Emerging new chemokine CXCR3 antagonists and their potential clinical and therapeutic applications
Shailendra Kapoor – 27 March 2009
Liver X receptor mediates hepatitis B virus X protein–induced lipogenesis in hepatitis B virus–associated hepatocellular carcinoma
Tae‐Young Na, Young Kee Shin, Kyung Jin Roh, Shin‐Ae Kang, Il Hong, Sae Jin Oh, Je Kyung Seong, Cheol Keun Park, Yoon La Choi, Mi‐Ock Lee – 27 March 2009 – Although hepatitis B virus X protein (HBx) has been implicated in abnormal lipid metabolism in hepatitis B virus (HBV)–associated hepatic steatosis, its underlying molecular mechanism remains unclear. Liver X receptor (LXR) plays an important role in regulating the expression of genes involved in hepatic lipogenesis. Here we demonstrate that LXRα and LXRβ mediate HBV‐associated hepatic steatosis.
Blockade of four‐transmembrane L6 family member 5 (TM4SF5)‐mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative
Sin‐Ae Lee, Hyung Won Ryu, Young Mee Kim, Suyong Choi, Mi Ji Lee, Tae Kyoung Kwak, Hyeon Jung Kim, Moonjae Cho, Ki Hun Park, Jung Weon Lee – 27 March 2009 – We previously reported that the four‐transmembrane L6 family member 5 (TM4SF5) was highly expressed in hepatocarcinoma, induced morphological elongation and epithelial‐mesenchymal transition, and caused abnormal cell growth in multilayers in vitro and tumor formation in vivo.
The perils and promise of high‐dimensional biology
Terry Therneau – 27 March 2009
Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma
Shunsuke Ura, Masao Honda, Taro Yamashita, Teruyuki Ueda, Hajime Takatori, Ryuhei Nishino, Hajime Sunakozaka, Yoshio Sakai, Katsuhisa Horimoto, Shuichi Kaneko – 27 March 2009 – MicroRNA (miRNA) plays an important role in the pathology of various diseases, including infection and cancer.
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats
Marc Mejias, Ester Garcia‐Pras, Carolina Tiani, Rosa Miquel, Jaime Bosch, Mercedes Fernandez – 27 March 2009 – Portal hypertension, the most important complication in patients with cirrhosis of the liver, is a serious and life‐threatening disease for which there are few therapeutic options.
Diagnosis, management, and treatment of hepatitis C: An update
Marc G. Ghany, Doris B. Strader, David L. Thomas, Leonard B. Seeff – 27 March 2009
Diagnosis, management, and treatment of hepatitis C: An update
Marc G. Ghany, Doris B. Strader, David L. Thomas, Leonard B. Seeff – 27 March 2009
A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature
Jean‐Louis Delaunay, Anne‐Marie Durand‐Schneider, Danièle Delautier, Alegna Rada, Julien Gautherot, Emmanuel Jacquemin, Tounsia Aït‐Slimane, Michèle Maurice – 27 March 2009 – Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare liver disease characterized by early onset of cholestasis that leads to cirrhosis and liver failure before adulthood. PFIC3 may be improved by chronic administration of ursodeoxycholic acid, although in many cases liver transplantation is the only therapy.
A crossing in therapy for hepatitis C virus genotype 2 or 3: Increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration
Chung‐Feng Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu – 27 March 2009